Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
The need to monitor the safety of new medicines in large
populations of patients is well established. Ayres et al (p 926) conducted a postmarketing surveillance study of the safety of the first
licensed, pressurised metered dose inhaler to use a non-chlorofluorocarbon propellant
the hydrofluoroalkane 134a
salbutamol sulphate inhaler (Airomir, 3M)
in primary care. They
observed outcomes in over 6000 patients who had been prescribed metered doses of salbutamol delivered by inhalers using either
hydrofluoroalkane or chlorofluorocarbon as the propellant. Their
findings supported the experience of clinical trials, showing that the
reformulation does not result in significant changes in safety compared
with metered dose inhalers using non-chlorofluorocarbon propellants.